Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response

Journal of Virology

Volumn 87, Issue 20, 2013, Pages 11076-11087

  Yan, Dan ^a   Krumm, Stefanie A ^a   Sun, Aiming ^b   Steinhauer, David A ^c   Luo, Ming ^d   Moore, Martin L ^c,e   Plemper, Richard K ^a,c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE;

ARTICLE; CLINICAL PROTOCOL; ENZYME ACTIVITY; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; INFLUENZA VIRUS A; MEASLES VIRUS; NONHUMAN; ORTHOMYXOVIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS ENTRY; VIRUS IDENTIFICATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS; MEASLES VIRUS;

EID: 84886920451     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01425-13     Document Type: Article

References (74)

1. Schwegmann A, Brombacher F. 2008. Host-directed drug targeting of factors hijacked by pathogens. Sci. Signal. 1:re8.
2. Tan SL, Ganji G, Paeper B, Proll S, Katze MG. 2007. Systems biology and the host response to viral infection. Nat. Biotechnol. 25:1383-1389.
3. Muller B, Krausslich HG. 2009. Antiviral strategies. Handb. Exp. Pharmacol. 2009:1-24.
4. Krumm SA, Ndungu JM, Yoon JJ, Dochow M, Sun A, Natchus M, Snyder JP, Plemper RK. 2011. Potent host-directed small-molecule in-hibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One 6:e20069. doi:10.1371/journal.pone.0020069.
5. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. 2011. Broadspectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 108:5777-5782.
6. Salerno D, Hasham MG, Marshall R, Garriga J, Tsygankov AY, Grana X. 2007. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Gene 405:65-78.
7. Schang LM. 2006. First demonstration of the effectiveness of inhibitors of cellular protein kinases in antiviral therapy. Expert Rev. Anti Infect. Ther. 4:953-956.
8. Prussia A, Thepchatri P, Snyder JP, Plemper RK. 2011. Systematic approaches towards the development of host-directed antiviral therapeutics. Int. J. Mol. Sci. 12:4027-4052.
9. Thompson WW, Comanor L, Shay DK. 2006. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J. Infect. Dis. 194(Suppl 2):S82-S91.
10. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-associated hospitalizations in the United States. JAMA 292:1333-1340.
11. Johnson D. 2009. Croup. Clin. Evid. (Online) 2009:0321. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907784/.
12. Bjornson CL, Johnson DW. 2008. Croup. Lancet 371:329-339.
13. World Health Organization. 2012. World Health Statistics 2012. WHO, Geneva, Switzerland. http://www.who.int/gho/publications/world_health _statistics/en/index.html.
14. MacDonald N, Hatchette T, Elkout L, Sarwal S. 2011. Mumps is back: why is mumps eradication not working? Adv. Exp. Med. Biol. 697:197-220.
15. De Clercq E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. 5:1015-1025.
16. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765.
17. Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, Kawakami C, Kiso M, Ito M, Hatakeyama S, Kawaoka Y. 2007. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin. Infect. Dis. 44:197-202.
18. Anderson LJ, Parker RA, Strikas RL. 1990. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis. 161:640-646.
19. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG, Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 329:1524-1530.
20. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Couchenour D, Tsao E, Hall WC, Young JF. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1215-1224.
21. Pleschka S, WolffT, Ehrhardt C, Hobom G, Planz O, Rapp UR, Ludwig S. 2001. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat. Cell Biol. 3:301-305.
22. Kujime K, Hashimoto S, Gon Y, Shimizu K, Horie T. 2000. p38 mitogen-activated protein kinase and c-jun-NH2-terminal kinase regulate RANTES production by influenza virus-infected human bronchial epithelial cells. J. Immunol. 164:3222-3228.
23. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. 2012. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J. Infect. Dis. 206:1844-1851.
24. Karlas A, Machuy N, Shin Y, Pleissner KP, Artarini A, Heuer D, Becker D, Khalil H, Ogilvie LA, Hess S, Maurer AP, Muller E, WolffT, Rudel T, Meyer TF. 2010. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature 463:818-822.
25. Konig R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, Garcia-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. 2010. Human host factors required for influenza virus replication. Nature 463:813-817.
26. Shapira SD, Gat-Viks I, Shum BO, Dricot A, de Grace MM, Wu L, Gupta PB, Hao T, Silver SJ, Root DE, Hill DE, Regev A, Hacohen N. 2009. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell 139:1255-1267.
27. Ludwig S. 2009. Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J. Antimicrob. Chemother. 64:1-4.
28. Barrows NJ, Le Sommer C, Garcia-Blanco MA, Pearson JL. 2010. Factors affecting reproducibility between genome-scale siRNA-based screens. J. Biomol. Screen. 15:735-747.
29. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. 6:29-40.
30. Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75:4399-4401.
31. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
32. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C, Christiansen G, Billeter MA. 1995. Rescue of measles viruses from cloned DNA. EMBO J. 14:5773-5784.
33. Hotard AL, Shaikh FY, Lee S, Yan D, Teng MN, Plemper RK, Crowe JE, Jr, Moore ML. 2012. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 434:129-136.
34. Yoon JJ, Krumm SA, Ndungu JM, Hoffman V, Bankamp B, Rota PA, Sun A, Snyder JP, Plemper RK. 2009. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob. Agents Chemother. 53:3860-3870.
35. Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B, Liotta DC, Snyder JP, Compans RW. 2004. A target site for templatebased design of measles virus entry inhibitors. Proc. Natl. Acad. Sci. U. S. A. 101:5628-5633.
36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
37. Ehrengruber MU, Hennou S, Bueler H, Naim HY, Deglon N, Lundstrom K. 2001. Gene transfer into neurons from hippocampal slices: comparison of recombinant Semliki Forest virus, adenovirus, adenoassociated virus, lentivirus, and measles virus. Mol. Cell. Neurosci. 17: 855-871.
38. Paal T, Brindley MA, St Clair C, Prussia A, Gaus D, Krumm SA, Snyder JP, Plemper RK. 2009. Probing the spatial organization of measles virus fusion complexes. J. Virol. 83:10480-10493.
39. Neumann G, Watanabe T, Kawaoka Y. 2000. Plasmid-driven formation of influenza virus-like particles. J. Virol. 74:547-551.
40. Fox T, Coll JT, Xie X, Ford PJ, Germann UA, Porter MD, Pazhanisamy S, Fleming MA, Galullo V, Su MS, Wilson KP. 1998. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci. 7:2249-2255.
41. Boutros M, Bras LP, Huber W. 2006. Analysis of cell-based RNAi screens. Genome Biol. 7:R66.
42. Pelz O, Gilsdorf M, Boutros M. 2010. web cellHTS2: a web-application for the analysis of high-throughput screening data. BMC Bioinformatics 11:185. doi:10.1186/1471-2105-11-185.
43. Zhang JH, Chung TDY, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73.
44. Dochow M, Krumm SA, Crowe JE, Jr, Moore ML, Plemper RK. 2012. Independent structural domains in paramyxovirus polymerase protein. J. Biol. Chem. 287:6878-6891.
45. Sutter G, Ohlmann M, Erfle V. 1995. Non-replicating vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase. FEBS Lett. 371: 9-12.
46. Kondo N, Miyauchi K, Matsuda Z. 2011. Monitoring viral-mediated membrane fusion using fluorescent reporter methods. Curr. Protoc. Cell Biol. Chapter 26:Unit 26.9. doi:10.1002/0471143030.cb2609s50.
47. Garcia-Sastre A. 2011. Induction and evasion of type I interferon responses by influenza viruses. Virus Res. 162:12-18.
48. Goodbourn S, Randall RE. 2009. The regulation of type I interferon production by paramyxoviruses. J. Interferon Cytokine Res. 29:539-547.
49. Ramachandran A, Horvath CM. 2009. Paramyxovirus disruption of interferon signal transduction: STATus report. J. Interferon Cytokine Res. 29:531-537.
50. Vreede FT, Chan AY, Sharps J, Fodor E. 2010. Mechanisms and functional implications of the degradation of host RNA polymerase II in influenza virus infected cells. Virology 396:125-134.
51. White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK. 2007. Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob. Agents Chemother. 51:2293-2303.
52. Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Montrose C, Moore RA, Weidner JR, Sittampalam GS. 2004. HTS assay validation, p 1-31. In Sittampalam GS, Gal- Edd N, Arkin M, Auld D, Austin C, Bejcek B, Glicksman M, Inglese J, Lemmon V, Li Z, McGee J, McManus O, Minor L, Napper A, Riss T, Trask OJ, Weidner J. (ed), Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD.
53. McGovern SL, Caselli E, GrigorieffN, Shoichet BK. 2002. A common mechanism underlying promiscuous inhibitors from virtual and highthroughput screening. J. Med. Chem. 45:1712-1722.
54. Coan KE, Maltby DA, Burlingame AL, Shoichet BK. 2009. Promiscuous aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem. 52:2067-2075.
55. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
56. Borden EC, Sen GC, Uze G, Silverman RH, RansohoffRM, Foster GR, Stark GR. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. 6:975-990.
57. Elliot RL. 2012. Four lessons from global health drug discovery: medicine for an ailing industry? Med. Chem. Lett. 3:688-690.
58. Lifson J, Coutre S, Huang E, Engleman E. 1986. Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. J. Exp. Med. 164:2101-2106.
59. Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U. S. A. 107:3157-3162.
60. De Clercq E. 2012. Human viral diseases: what is next for antiviral drug discovery? Curr. Opin. Virol. 2:572-579.
61. Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53:2719-2740.
62. Esper FP, Spahlinger T, Zhou L. 2011. Rate and influence of respiratory virus co-infection on pandemic (H1N1) influenza disease. J. Infect. 63: 260-266.
63. Sato H, Masuda M, Kanai M, Tsukiyama-Kohara K, Yoneda M, Kai C. 2007. Measles virusNprotein inhibits host translation by binding to eIF3-p40. J. Virol. 81:11569-11576.
64. Griffin DE. 2007. Measles virus, p 1551-1585. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed, vol 1. Lippincott Williams & Wilkins, Philadelphia, PA.
65. Wechsler SL, Fields BN. 1978. Intracellular synthesis of measles virusspecified polypeptides. J. Virol. 25:285-297.
66. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, Burkard TR, Burckstummer T, Stefanovic A, Krieger S, Bennett KL, Rulicke T, Weber F, Colinge J, Muller M, Superti-Furga G. 2011. IFIT1 is an antiviral protein that recognizes 5=-triphosphate RNA. Nat. Immunol. 12:624-630.
67. Abbas YM, Pichlmair A, Gorna MW, Superti-Furga G, Nagar B. 2013. Structural basis for viral 5=-PPP-RNA recognition by human IFIT proteins. Nature 494:60-64.
68. Martinez-Gil L, Ayllon J, Ortigoza MB, Garcia-Sastre A, Shaw ML, Palese P. 2012. Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One 7:e49049. doi:10.1371/journal.pone.0049049.
69. Bedard KM, Wang ML, Proll SC, Loo YM, Katze MG, Gale M, Jr, Iadonato SP. 2012. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J. Virol. 86:7334-7344.
70. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ. 2012. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One 7:e36594. doi:10.1371/journal.pone.0036594.
71. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. 1994. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45:649-656.
72. Babudri N, Pani B, Tamaro M, Monti-Bragadin C, Zunino F. 1984. Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells. Br. J. Cancer 50:91-96.
73. Broom WJ, Auwarter KE, Ni J, Russel DE, Yeh LA, Maxwell MM, Glicksman M, Kazantsev AG, Brown RH, Jr. 2006. Two approaches to drug discovery in SOD1-mediated ALS. J. Biomol. Screen. 11:729-735.
74. Soelaiman S, Wei BQ, Bergson P, Lee YS, Shen Y, Mrksich M, Shoichet BK, Tang WJ. 2003. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 278:25990-25997.